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Utrophin gene is transcribed in a large mRNA of 13 kb that codes for a protein of 395 kDa. It shows amino acid identity with dystrophin of up
to 73% and is widely expressed in muscle and non-muscle tissues. Up71 is a short utrophin product of the utrophin gene with the same cysteine-
rich and C-terminal domains as full-length utrophin (Up395). Using RT-PCR, Western blots analysis, we demonstrated that Up71 is overexpressed
in the mdx diaphragm, the most pathological muscle in dystrophin-deficient mdx mice, compared to wild-type C57BL/10 or other mdx skeletal
muscles. Subsequently, we demonstrated that this isoform displayed an increased expression level up to 12 months, whereas full-length utrophin
(Up395) decreased. In addition, β-dystroglycan, the transmembrane glycoprotein that anchors the cytoplasmic C-terminal domain of utrophin,
showed similar increase expression in mdx diaphragm, as opposed to other components of the dystrophin-associated protein complex (DAPC)
such as α-dystrobrevin1 and α-sarcoglycan. We demonstrated that Up71 and β-dystroglycan were progressively accumulated along the
extrasynaptic region of regenerating clusters in mdx diaphragm. Our data provide novel functional insights into the pathological role of the Up71
isoform in dystrophinopathies.
© 2005 Elsevier B.V. All rights reserved.Keywords: Utrophin isoform; Beta-dystroglycan; Muscle; Mdx; Sarcolemma; DMDDuchenne muscular dystrophy (DMD) is the most prevalent
inherited neuromuscular disorder, affecting ∼1 in every 3,500
male births [1]. The disease results from mutations and/or
deletions in the X-linked dystrophin gene, which prevents
production of large cytoskeletal proteins of the spectrin
superfamily [2,3]. Although the exact function of dystrophin
remains unclear, it has been shown to serve as a link between
the internal actin cytoskeleton and the extracellular matrix via aAbbreviations: mdx, X-chromosome-linked muscular dystrophy; Up,
utrophin product; NMJ, neuromuscular junction; DMD, Duchenne muscular
dystrophy; DAPC, dystrophin-associated protein complex; TA, Tibialis
anteriors; MHC, myosin heavy chain; β-DG, beta-dystroglycan; α-SG, alpha-
sarcoglycan; NBT, p-nitroblue tetrazolium; BCIP, 5-bromo-4-chloro-3-indoyl-
phosphate substrate; NFATc1, nuclear factor-activated T cells 1; MyoD,
myogenic differentiation protein
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Through these interactions, dystrophin is thought to maintain
the integrity of muscle cell membrane during the cycles of
contraction and relaxation. Moreover, accumulating evidence
suggests that some DAPC component has an important
signaling role in muscle and is not merely a molecular scaffold
serving the mechanical function [6].
In 1989, a gene that encodes a large cytoskeletal protein
showing extensive sequence identity with dystrophin was
identified on chromosome 6 [7,8]. Interestingly, this protein,
now referred to as utrophin, is more ubiquitously distributed
than full-length dystrophin. In skeletal muscle fibers, utrophin
also displays a clear difference in its pattern of distribution as
compared with dystrophin. Whereas dystrophin is known to be
expressed along the entire length of the sarcolemma in normal
muscle fibers, utrophin preferentially accumulates at the
neuromuscular junction in both normal and DMD muscles
Fig. 1. β-DG, α-DB and α-SG in 2-month-old mdx and C57BL/10 mice. (A) Immunofluorescence detection of β-DG on cryostat sections of diaphragm and tibialis
anterior (TA) from mdx and wild-type C57BL/10 mice. As shown, high immunostaining of β-DG in mdx diaphragm was observed in comparison with TA muscle
sections. (B) Western blotting of α-DB1, α-SG and β-DG corresponds to total protein extracts of TA (tibialis anterior) and D (diaphragm) muscles. Quantification of
protein bands by the NIH Image software package to determine the relative optical density of the protein band (arbitrary unit) is presented under the blots (histograms).
The results are mean±S.E.M. of two independent experiments performed in triplicate. Asterisks denote significant difference (P≤0.05) and NS indicates no
significant result with the unpaired t-test.
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Fig. 2. Utrophin distribution in C57BL/10 and mdx diaphragm and tibialis
anterior membrane. (A) NMJ viewed by the C-terminal utrophin antibody
(images a and c) and fluorescein α-bungarotoxin (images b and d) on serial
cryostat sections C57BL/10 diaphragm and tibialis anterior muscles C57BL/
10. (B) Utrophin stains on mdx diaphragm and tibialis anterior muscles with
C-terminal (images a and c) and N-terminal (images b and d) antibodies
showing the utrophin distribution along the extrasynaptic region. Importantly,
only C-terminal antibody showed high fiber staining in mdx diaphragm (image
a, dashed square).
364 K. Hnia et al. / Biochimica et Biophysica Acta 1762 (2006) 362–372[4,9,10], where it may contribute to the full differentiation of the
postsynaptic apparatus [11,12]. Because of its high degree of
identity with dystrophin [13], it has been suggested that
upregulation of utrophin into extrasynaptic regions of DMD
muscle fibers could serve as an adequate therapeutic strategy for
this disease [10,14,15]. There has been considerable interest in
understanding the mechanisms regulating the expression of
utrophin in skeletal muscle. Several studies have shown that
utrophin levels can be modulated according to the state of
innervations, myogenic differentiation and the oxidative capac-
ity of muscle cells [16–19]. In this context, regenerating muscle
showed higher levels of utrophin but no increase in full-length
utrophin mRNA was observed, leading to suggestions of post-
transcriptional regulatory mechanisms or the presence of other
utrophin transcription products [20]. Specific transcription
factors and promoter elements were found to be involved in
regulating the abundance and localization of utrophin transcripts
within muscle fibers [21]. Recent studies have characterized C-
terminal utrophin expression in normal and dystrophin-deficient
mdx mouse tissues and have suggested a more complex array of
utrophin gene products [22,23]. There is still much to be learned
about utrophin gene regulation, in particular regarding alterna-
tive isoforms and their role in muscle cell membrane. Several
groups have observed small gene products using antibodies
raised against the utrophin C-terminus. Up71 is a short transcript
of utrophin with a unique first exon located in intron 62 and
predicted to encode a 4.0 kb mRNA and a 71 kDa protein with
the same cysteine-rich and C-terminal domains as full-length
utrophin, commencing with exon 63 (dystrophin exon number-
ing) [24]. These domains are implicated in interactions with β-
dystroglycan (β-DG), the transmembrane glycoprotein that
anchors utrophin and dystrophin in muscle cell membrane
[25,26]. Like full-length utrophin, Up71 isoform has an
ubiquitous expression and was detected by our team and others
in the peripheral nervous system and small peripheral arteries
[24,27,28]. To date, there is little information about the
expression of this short transcript in dystrophin deficient muscle
and its implication in DMD pathology.
Several studies have shown that not all muscles that lack
dystrophin are equally susceptible to muscle degeneration. The
mdx mouse exhibits great variability in myofiber necrosis and
contractile properties betweendifferentmuscles [29]. Thesemice
exhibit a mild form of muscular dystrophy, as seen by elevated
serum level of creatine kinase and histological changes consistent
withmyofiber damage.Thehind limbmuscles undergo extensive
myofiber degeneration and regeneration from 3 to 5weeks of age
[30]. Although hind limb muscles of mdx mice undergo
successful regeneration, the mdx diaphragm exhibits high
dystrophic pattern and responds to progressive muscle degener-
ation with transition to a slower phenotype associated with
reduced power output and greater endurance [31–33]. Interest-
ingly, the diaphragm frommdxmice reproduces the degenerative
pattern observed in DMD [34,35] which suggest that the early
dystrophic changes are most prominent in this muscle [33].
In this study, we demonstrated that the short utrophin
isoform Up71 was overexpressed in mdx mouse diaphragm
compared to wild-type C57BL/10 or other mdx skeletalmuscles. We showed that Up71 and β-DG were accumulated
in regenerative clusters and not exclusively in slow oxidative
MHC (myosin heavy chain) type I fibers, as described
previously for utrophin A in soleus muscle [19]. These results
argue for a possible involvement of Up71 and β-DG in the
regenerative process in mdx diaphragm and consequently may
shed light on the pathological pattern of this muscle.
1. Materials and methods
1.1. Laboratory animals
Control (C57BL/10) and mdx mice were purchased from Jackson
Laboratory (Bar Harbor, USA) and used at 2, 6, 8, 10, 12, 14 and 16 months
Fig. 3. Up71, Up395 and β-DG expression in mdx diaphragm. (A) Western blot detection of utrophin isoforms by C-terminal utrophin antibody. Only the full-length Up395 isoform in mdx TA samples was detected,
whereas mdx diaphragm (from 6 to 16 months) presented an additional protein band with Mr 70 kDa (Up71). In addition, a decline in full-length utrophin level was observed while the short isoform Up71 increase during
the same time. (B) Western blot detection with N-terminal utrophin antibody showed only full-length utrophin Up395 in both mdx diaphragm and TA samples. C: β-DGWestern blots in mdx diaphragm extracts from 6-
to 16-month-old mice revealed an increase in level up to 12 months. D: RT-PCR analysis of Up71, Up395 and β-DG transcripts. PCR products after cDNA amplification of Up71, Up395 and β-DG of 6- and 12-month-
old mdx diaphragm samples revealed the abundance of Up71 and β-DG transcripts at these ages compared with full-length utrophin transcript. Increased expression of Up71 and β-DG was noted between 6- and 12-
month-old mdx diaphragms, whereas Up395 was decreased. The 100-pb molecular mass markers (Promega) were used to estimate the molecular mass of the PCR products. Graphical representations show Western blot
and PCR band quantification; the results are mean±S.E.M. of two independent experiments performed in triplicate. Asterisks denote significant difference (P≤0.05). 365
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366 K. Hnia et al. / Biochimica et Biophysica Acta 1762 (2006) 362–372of age. At each selected age, 5 animals were killed and tissues were analyzed
separately. Diaphragms and TA muscles were dissected and divided into 2 parts.
One part was rapidly frozen in 2-methylbutane, cooled in liquid nitrogen and
stored at −80 °C until use for immunohistochemical analysis, total protein
preparation and RT-PCR analysis. The second part was immediately used for co-
immunoprecipitation analysis. New Zealand white rabbits were used to produce
polyclonal antibodies.
1.2. Antibodies
Polyclonal antibodies against β-DG (LG5), α-SG (Sarco3) and α-DB1
(D1) were produced and characterized as previously described [36].
Polyclonal antibody against the utrophin C- and N-terminal ends
(respectively named K7 and B1) were produced as follows. Utrophin C-
terminal end (residues 3423–3433) was used as a specific antigenic
sequence and the K7 antibody was obtained by injecting the KLH-linked
peptide as antigen, according to a previously described protocol [37]. The
utrophin B1 antibody was produced as a recombinant protein. The
corresponding DNA sequence (5302–5810; accession number NCBI
X69086) coding for residues 1767–1810 of human utrophin was produced
by RT-PCR using human total RNA from muscle cDNA, as previously
described [38,39]. All antibodies were tested in competition with
corresponding synthetic peptides on cryostat sections or Western blots.
No immunofluorescence labeling or protein bands were observed when
peptides were applied. Antibodies against slow MHC I and fast MHC II
isoforms were purchased from Sigma. MyoD antibody was purchased from
BD Bioscience and desmin antibody from Chemicon International.1.3. Histochemistry and MHC electrophoresis separation
ATPase myosin heavy chain (MHC) activity on a fresh serial cryostat section
of muscles was used to determine fiber type in two conditions, an acid pH of 4.6
and a basic pH of 9.4, according to a previous protocol [40,41]. MHC
electrophoresis was performed according to a previously described protocols
[29]. Myosin was isolated according to D'Albis et al. [42]. MHC isoforms were
separated in 8%SDS-PAGE; gels were stainedwith a Biorad Silver Stain Plus Kit
and scanned with the Fotolook/AGFA Duoscan system [43]. The percentages of
the different MHC isoforms were quantified by the NIH Image program.
1.4. Immunofluorescence light microscopy
Cryostat sections (10 μm) of unfixed muscles were labeled with the
antibodies described above. Immunoreactions were detected with Cy3- or FITC-
conjugated sheep anti-rabbit IgG (Euromedex). Neuromuscular junctions were
visualized with coupled bungarotoxin-fluorescein (FITC) (Sigma).
1.5. Total protein extract and Western blotting
0.01 g of fresh muscle tissue was homogenized in 150 μl of 5% SDS
buffer (50 mM Tris/HCl, pH 8.0, 10 mM EDTA, 5% SDS) supplemented
with 1% trypsin inhibitor and 1% saponin. After centrifugation (10 min at
13000×g), protein concentration was estimated in the supernatant using the
BCA protein assay kit (Pierce). 50 μl of SDS buffer containing 0.01%
bromophenol blue, 10% glycerol and 5% beta-mercaptoethanol was added to
the supernatant and each sample was denatured for 5 min at 100 °C. Protein
Fig. 4. Co-immunoprecipitation of utrophin isoforms and β-DG. Western blots
revealed by C-terminal utrophin and β-DG antibodies in membrane
homogenate (Mh) and after co-immunoprecipitation of utrophin products
with β-DG (IP-β-DG) respectively in mdx diaphragm (panel A) and tibialis
anterior (panel B) mdx muscles. Panel A showed that Up71 was present in both
membrane homogenate (Mh) and eluted fraction of immunoprecipitation assay
with β-DG antibody (IP-β-DG). In a second part, Mh and eluted fraction were
revealed by an antibody directed against β-DG. The same experiments were
applied on tibialis anterior muscle (panel B). No Up71 was detected in Mh and
after IP-β-DG.
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resulting gel was Coomassie blue stained and the other was transferred onto
0.2 μm nitrocellulose membrane. Each blot was blocked in Tris-buffered
saline with 0.1% Tween 20 (TBST) containing 3% bovine serum albumin (w/
v). All membranes were incubated with primary antibodies for 1 h at room
temperature. After labeling, the membranes were washed in TBST and then
incubated with a phosphatase-labeled second antibody (Jackson ImmunoR-
esearch Laboratory, appropriate dilution). Antibody-bound proteins were
detected with NBT/BCIP substrate.
1.6. Immunoprecipitation
Immunoprecipitation was performed using monoclonal antibody 43DAG/
8D5 as previously described [44,45]. Crude muscle membrane fraction was
prepared from fresh tissues homogenized in a Triton X100 lysis buffer (120 mM
NaCl and 1% Triton X100) supplemented with 10 mM iodoacetamid, 1%
saponin, 1% trypsin inhibitor, 20 mM PMSF and 1% leupeptin. Homogenates
were centrifuged at 140000×g for 30 min at 4 °C. The supernatant was
incubated with 43DAG/8D5 antibody overnight at 4 °C with gentile agitation.
The protein–antibody complex was mixed with magnetic protein A micro-beads
(MACS: Miltenyi Biotec). After extensive washing with a buffer containing
0.1% Triton X100, 50 mM Tris/HCl pH 8, 120 mM NaCl, 0.75 mM bezamedine
and 0.1 mM PMSF, the magnetically labeled immune complex was purified
over a micro-column placed in the magnetic field of the MACS separator. The
bound fractions were eluted by a buffer containing 0.1% Triton X100, 50 mM
Tris/HCl pH 7.4, 0.35 N-acetyl-D-glucosamine, 0.75 mM bezamedine and 0.1
mM PMSF. The experiments were performed in duplicate using 12-month-old
mdx mice.
1.7. RT-PCR
Total RNA was isolated from cryoconserved muscle with SV total RNA
isolation kit (Promega) following the manufacturer's instructions. We used 0.1
microgram of total RNA to generate first strand cDNA sequences with random
hexanucleotide primers and the M-MLV reverse transcriptase (invitrogen). Of the
RT reaction, 12 μl were subsequently used for each PCR reaction in 25μl using
the Taq Polymerase from Qbiogene. Three PCR reactions were performed to
amplify the mouse Up395 isoform using the primers (mUp-ex17/20-F and mUp-
ex17/20-F) previously described [24], the mouse Up71 using a forward primer
located in the unique first exon (FUP71, 5′-TTGAATACTGAGTAATAATT-
GAGT-ACTAG-3′), and a reverse primer located in exon 63 RUp71, 5′-
AAGAGCT-CATTTTAGGATGAT-3′); and the mouse β-DG gene (Fdag1-5′-
GGAGGCTGT-TCCCACCGTGGT-3′; Rdag1, 5′-CTCTGCATTCT-GTTC-
AACAGATCG-3′. The obtained PCR products were of 383-pb (mUp395),
220-pb (mUp71) and 474-pb (dag1), respectively. PCR conditions included 94
°C for 5 min, 35 cycles of 94 °C for 30s, 60 °C for 30s, 72 °C for 1 min, and a
final extension of 72 °C for 8 min. Amplification of the ubiquitously expressed
phosphoglucomutase (PGM1) gene using the specific primers which amplify
mouse PGM1 as previously described [24]. Negative controls in which total
RNA was replaced with RNAse-free water or reactions mixtures without RT (for
DNA contamination) were performed. PCR products were visualized on 1.5%
agarose gel. The 100-pb molecular mass markers (Promega) were used to
estimate the molecular mass of the PCR products.
1.8. Morphometrical analysis
Ten-μm transversally cryostat sections of mdx TA and diaphragm in each
age were stained by hematoxylin and eosine (H&E), which allow to
distinguish between healthy myofibers, showing peripheral nuclei, regenera-
ting myofibers, and degenerating fibers, often present in areas where also
small regenerating fibers and cell infiltrates were visible. Morphometrical
analysis was performed on 10 cross-sections from each TA and diaphragm.
The following parameters were evaluated and treated as previously described
[46–48]: (1) percentage of centrally nucleated fibers referred to the total
number, (2) percentage of total non-muscle area (fibrotic or adipose tissue)
and (3) variance coefficient of the muscle fiber size determined with the
minimal fret's diameter method [47].1.9. Scanning densitometry and statistical analysis
Using the NIH Image software package, the relative optical density of the
protein band on Western blot membranes was calculated. Values are means±S.
E.M. Student's t-test was used (Pb0.05 was considered significant).2. Results
2.1. Conserved β-DG level in mdx diaphragm
Immunofluorescence studies showed a decrease in α-DB1
and α-SG at the sarcolemma of both mdx diaphragm and TA
compared with C57BL/10 muscles (not shown). Interestingly,
β-DG seemed to be maintained in the mdx diaphragm
membrane but not in the other mdx skeletal muscles such as
TA (Fig. 1A). Western blot detection and protein quantification
in each muscle confirmed this result and revealed a decreasing
level of α-DB1 and α-SG in diaphragm and TA, whereas the β-
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significantly decreased in TA compared with wild-type
C57BL/10 muscle (Fig. 1B).2.2. Utrophin accumulation in mdx diaphragm sarcolemma
Immunofluorescence using utrophin antibodies and α-
bungarotoxin showed labeling of neuromuscular junctions in
all C57BL/10 muscle sections (Fig. 2A). The labeling
intensity between C-terminal and N-terminal antibodies was
similar in mdx TA muscle (Fig. 2B, images c and d,
respectively) but clearly different in diaphragm (Fig. 2B,
images a and b). Interestingly, some specific areas and some
cells appeared more intensively stained with C-terminal
antibody but not with N-terminal antibody (Fig. 2B, dashed
square).
2.3. Short utrophin isoform (Up71) in mdx diaphragm
A 70-kDa utrophin isoform was detected by the C-terminal
antibody (K7) in mdx diaphragm but not in the mdx TA muscle
extract (Fig. 3A). Up71 was detected in all analyzed mdx
diaphragms, and it steadily increased between 6- and 12-
month-old mice (Fig. 3A). Moreover, using the N-terminal
antibody (B1) on the same extracts, the 70-kDa band was not
detected in diaphragm or TA (Fig. 3B). Subsequently, β-DG
Western blot detection on 6- to 16-month-old diaphragm
extracts showed an increasing level of this protein until 12
months old (Fig. 3C).
To further confirm our results, we performed RT-PCR
analyses of Up71, β-DG and Up395 mRNA in mdx muscles
using specific primers for each transcript. Up71 mRNA was
highly detected in 6- and 12-month-old mdx diaphragms (Fig.
3D, left panel) but was weakly expressed in the other skeletal
muscles (Tibialis anterior, Vastus lateralis) and C57BL/10
muscles (not shown). In contrast, Up395 expression was
decreased from 6- to 12-month-old mdx diaphragms (Fig. 3D,
right panel). The β-DG expression was very similar to that of
Up71, with an increase up to 12 months (Fig. 3D, central
panel). These results led us to assume that the intensive
labeling of C-terminal utrophin antibody along the extra-
synaptic region of mdx diaphragm fibers was due to the
presence of the Up71 utrophin isoform, in accordance with
previous results.Fig. 5. Utrophin/β-DG accumulation and mdx diaphragm fiber types. (A)
Relative proportion of diaphragm fiber types in 6- and 12-month-old mdx mice
compared with C57BL/10. MHC isoforms were separated on 8% gel
electrophoresis and the histogram shows the relative percentages of MHC
isoforms of mdx and C57BL/10 diaphragms. (B) Serial cross-sections of 12-
month-old mdx stained with FITC-MHC I (a), FITC-MHC II (b), Cy3-C-
terminal utrophin (c) and Cy3-β-DG antibodies (d). Asterisks show MHC I
fibers without specifically high levels of utrophin and/or β-DG in their
membranes. Dashed square and white arrowhead show fibers with high
expression pattern of utrophin and β-DG in their membranes. (C) Serial sections
show ATPase activity (pH 4.6) of 12-month-old mdx diaphragm fibers (a),
utrophin C-terminal (b) and β-DG antibodies (c). MHC IIa fibers have a milder
ATPase activity in acid conditions (pH 4.6) and present an intermediate
coloration, while MHC IIb fibers have white coloration. Asterisks show MHC I
fibers (a) with a weak labeling of utrophin and β-DG in their membranes. Big
arrows show some glycolytic MHC IIb/IIx fibers with a milder level of utrophin
and β-DG expression pattern and hatched arrows show fibers with high utrophin
and β-DG expression pattern.
Fig. 6. Up71 and β-DG accumulation in regenerative/degenerative clusters of
mdx diaphragm. (A) Serial sections of 12-month-old mdx diaphragm were
labeled with desmin antibody revealed with FITC-conjugated antibody (a) and
utrophin C-terminal antibody revealed with Cy3-conjugated antibody (b).
Desmin labeling showed regenerative fibers (dashed square) with a high level of
utrophin. When examined with H&E staining, these aggregate fibers were in
majority centro-nucleated (white arrows). (B) Western blot detection of MyoD
in 6-month-old and 12-month-old mdx diaphragm compared with age-matched
(12 months) mdx tibialis anterior (TA) and C57BL/10 diaphragm.
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In an attempt to establish a relationship between Up71 and
β-DG, we performed a co-immunoprecipitation assay using
43DAG/8D5 C-terminal β-DG antibody in diaphragm and TA
muscle membrane preparations. Twelve-month-old mdx mice
were selected according to the relative abundance of Up71
isoform. Our results showed that Up395 immunoprecipitated
with β-DG antibody in the TA samples, whereas Up71 was
largely detected in mdx diaphragm (Fig. 4A).
2.5. Up71 and β-DG are not preferentially accumulated in mdx
diaphragm MHC I fibers
In order to establish a correlation between the time course
expression of Up71 and MHC I fiber colonization of mdx
diaphragm, we tested the level of MHC isoforms. In 6-month-
old C57BL10 diaphragm, we observed a predominance of MHCIIa, MHC IIx and MHC IIb isoforms, whereas the MHC I
phenotype was weakly represented (Fig. 5A). The 12-month-old
mdx mice exhibited a number of important differences in MHC
expression compared with the young mdx and control mice. The
percentage of type I and type IIa MHC fibers was significantly
higher in the 12-month-old mdx diaphragm; however, the IIb
fiber population was even absent in the old mdx animal. In a
second step of the experiment, serial sections of 12-month-old
mdx diaphragm were labeled with MHC I (a), MHC II (b), C-
terminal utrophin (c) and β-DG (d) antibodies (Fig. 5B). There
was no evident relationship between utrophin and β-DG
sarcolemmal accumulation with MHC type I fibers. Moreover,
ATPase fiber activity on serial section showed that some MHC
IIa and MHC IIb/IIx fibers have a high utrophin isoform and β-
DG expression pattern in their sarcolemma (Fig. 5C).
2.6. Up71 is accumulated in regenerative clusters of mdx
diaphragm
Serial sections labeled with C-terminal utrophin antibody and
desmin antibody showed strong utrophin labeling in the
multinucleated and central nucleated fibers observed in muscle
regenerative processing (Fig. 6A) indicating a regenerative
activating process in 12-month-old mdx diaphragm. These data
demonstrate a possible implication of Up71, which is the major
utrophin product, in association with β-DG in the regenerative
process which takes place in mdx diaphragm. Western blot
detection of MyoD (Fig. 6B) showed a significant increase in its
level from 6-month- to 12-month-old mdx diaphragm in
comparison with the level in C57BL/10 diaphragm and TA
muscle. Importantly themorphometrical studyofmdxdiaphragm
comparedwithTAmuscle showed that in 12-month-oldmice this
muscle showed an accentuated dystrophic pattern, elevated
percentage of central nuclei fibers, invasion of connective tissue
and high muscle fiber sizes heterogeneity (See Table 1).
3. Discussion
Although murine X-linked muscular dystrophy (mdx) and
DMD muscle are both characterized by complete absence of
dystrophin, the limb muscle weakness and progressive
degeneration of adult mice is different from DMD muscles.
The mdx diaphragm exhibits degenerative pattern similar to
DMD skeletal muscle. Molecular mechanisms implied in this
phenotypic difference are of major importance and may
contribute to develop new therapeutic strategy to slow down
or stop degenerative process in DMD muscles.
In the present study, we demonstrated that in mdx mice, β-
DG expression was dramatically reduced in skeletal muscles
such TA and VL but not in diaphragm. The short utrophin
isoformUp71 is detected in mdx diaphragm but not in other mdx
nor in C57BL/10 muscle. Wilson et al. have detected the mRNA
of Up71 and the Up140 (another short utrophin transcript)
transcripts in adult and fetal human and mouse tissue. In that
study no western blot detection of these isoforms was shown and
no precision about the analyzed muscles was cited. In another
hand the authors showed that the Up71 mRNA was weakly
Table 1
Morphometrical parameter of TA and diaphragm from 2- to 16-month-old mdx mice
Mdx mice age
(months)
Variance
coefficient TA
Variance
coefficient DIA
% Centrally nucleated
fibers TA
% Centrally nucleated
fibers DIA
Non-muscle area TA
(cm2)
Non-muscle area DIA
(cm2)
2 375±12 367±14 42±3 35±2 0.633±0.073 0.745±0.064
6 395±15 412±17 34±2 25±4 0.007±0.083 0.342±0.078
8 425±11 460±21 45±5 55±6 0.0232±0.091 0.364±0.082
10 456±11 460±21 55±4 72±7 0.442±0.12 0557±0.094
12 485±17 519±26 70±8 91±4* 0.625±0.101 0872±0.105
14 490±23 525±32 75±7 92±11 0.675±0.097 0.916±0.103
16 500±31 527±33 85±9 90±12 0.713 ± 0.113 0.937±0.110
Variance coefficient of the muscle fiber sizes determined with the minimal ‘Fret's diameter’ method in Tibialis anterior (TA) and diaphragm muscles from 2- to 16-
month-old mdx mice. Percentage of centrally nucleated fibers and non muscle area (the space occupied by connective tissue over a standard section of 8 cm2)
determined in hematoxylin–eosin-stained sections (at least ten sections for each muscle and five animals per age) are also quantified to establish a comparative profile
of the dystrophic pattern progression in these tow muscles. At 12 months old, mdx mice diaphragm showed a significant difference of the dystrophic pattern compared
to age matched TA muscle.
Significantly different by impaired Student's t-test for *Pb0.05.
370 K. Hnia et al. / Biochimica et Biophysica Acta 1762 (2006) 362–372expressed in muscle tissue. In our study we have analyzed three
skeletal muscles, TA, VL (Not shown) and diaphragm in normal
and mdx mice (from 2 to 12 months old). Despite the mdx
diaphragm no Up71 was detected in western blot in the other
tissue. In accordance with Wilson et al. the RT-PCR analysis
showed a very weak expression of this isoform in all normal
muscles, but in mdx mouse diaphragm, Up71 was largely
expressed. This difference suggests that posttranscriptional and
posttranslational events could take place in the regulation of
Up71 in diaphragm and the other skeletal muscles. To date, this
is the first demonstration that Up71 is specifically expressed
along the extrasynaptic region of mdx diaphragm and its
expression correlates with evolution of pathological pattern of
this muscle according to the morphometrical study (see Table 1).
Subsequently, full-length utrophin (Up395) showed a decreased
expression in mdx diaphragm while it remains stable in age-
matched mdx TA muscles. The short transcript Up71 is
predicted to encode protein that has lost the N-terminal actin-
binding domain and part of or the entire long spectrin-like rod
region. Up71 retains sequences that encode the C-terminal
domain that mediates binding to membrane proteins and it
seems probable that their cellular function involves interactions
with cell membrane, especially with β-DG. As in Up71, the
Dp71 (dystrophin product with a Mr 71 kDa) did not contain the
N-terminal part of the parental molecule (dystrophin full length),
and fails to link F-actin. Then, even with partial restoration of the
DAPC such Dp71 transgenes fail to prevent muscle degener-
ation [49–51]. It is possible that the pathological pattern of the
mdx diaphragm is due to the concurrent presence of full-length
utrophin and the short isoform Up71. By co-immunoprecipita-
tion analysis, our results showed that Up71 may compete with
Up395 in β-DG site attachment in mdx diaphragm sarcolemma.
In the other analyzed muscles immunoprecipitation with the β-
DG antibody showed exclusively the Up395 in the crude
membrane fraction. Likeness in the dystrophic process between
mdx diaphragm and DMD muscle led suggested the same
competition between full and short length utrophin for β-DG
anchoring at the cell membrane of DMD muscle.
In our experiment we demonstrated that Up71 and β-DG
accumulation does not specifically concern slow oxidativeMHC
I fibers, as previously described with utrophin A expression insoleus muscle [19]. The utrophin A promoter contains an NFAT-
binding site, and calcineurin and NFATc1 can increase the
transcriptional activity of this promoter in cultured myogenic
cells, as well as in oxidative slowMHC I fibers of soleus muscle
[19,49–53]. In our experiment, no specific activation of the
calcineurin/NFATc1 pathway was observed between 6- and 12-
month-old mdx diaphragms (Not shown) which demonstrate
that utrophin A and the short isoform Up71 are differently
regulated in muscle cells and possibly also during muscle
development. Previous reports have shown in regenerating
fibers that increase in full-length utrophinmRNA is transient and
relatively rapid and that 1 week after muscle damage, utrophin
returns to a low level [20]. This kinetic induction correlates with
satellite cell activation. Thus, utrophin transcription is already
activated in satellite cells before or at the time of fusion into
fibers, suggesting that most of the utrophin present along the
newly formed fibers is already synthesized at the time of
myoblast fusion to myotubes [20]. However, further investiga-
tions about the role of the short utrophin isoforms in satellite cell
differentiation and myotubes formation should clarify the
implication of these isoforms in myogenesis, as recently
described for short dystrophin isoform, Dp71 [54].
The mdx diaphragm reproduces the degenerative pattern
observed in DMD muscles and showed a high regenerative/
degenerative pattern. We tried to correlate Up71 and β-DG
overexpression and the expression pattern of MyoD and desmin.
Our results showed a high Up71 staining along the extrasynaptic
regions of regenerating fibers of mdx mice diaphragm according
to desmin labeling and H&E staining in 12-month-old mdx
diaphragm sections. These observations lead us to propose that
β-DG may specifically anchor the short utrophin isoform Up71
in regenerative clusters of mdx diaphragm sarcolemma. Since
diaphragm is one of the organs with higher presence of Up71,
among striated muscle studied, we decided to start a length-term
study focusing on the identification of any potential function of
Up71 in diaphragm. Interestingly the heregulin and the
phosphatase inhibitor, the okadoic acid and the GTPase Rho,
all these signaling molecules have recently been described as
activators of utrophin promoter A [55–58]. GTPase Rho is also
found crucial for myogenesis induction such as the muscle-
determining Factor MyoD, as well as that of few other muscle-
371K. Hnia et al. / Biochimica et Biophysica Acta 1762 (2006) 362–372specific genes [59]. Then, the plasma membrane association and
the stability of utrophin is significantly increased upon effect of
an activate form of RhoA GTPase [58]. Even cytochalasin B
treatment, which disrupt the F-actin cytoskeleton, appears to
translocate utrophin from the plasma membrane, indicating that
utrophin localization is dependent one the assembly of the F-
actin submembranous distribution [58]. However, the Up71
found in abundancy in diaphragm was not containing the actin
binding site present only in full-length utrophin. So, the
competitive binding to beta-dystroglycan between utrophin
and Up71 to be anchor at the muscle cell membrane may involve
lost in the F-actin network stability when Up71 win. The
observation that significant amount of Up71 along the plasma
membrane places this protein on the list of potential competitor
toward utrophin leading to maintain membrane instability due to
dystrophin deficiency. Then in diaphragm, the compensation of
dystrophin loss by replacement with utrophin cannot be reached
because of Up71 presence. This is mainly due to the particularity
of this muscle. In fact it is now established that mechanical stress
applied axially and transversally to skeletal muscle fibers
involves distinct signaling pathway in response [60]. In
particular, diaphragm, that is have axial muscle that answer to
both axial and transverse mechanical forces reveals also even
more specific signal transduction pathways in response to
various environmental stimuli and this feature was clearly
demonstrate for example when integrin alpha7 is absent [61]. In
addition diaphragm was described as the most damaged muscle
among all other dystrophin-deficient muscles in mdx mice.
There is more regeneration cell clusters in this muscle in attempt
to maintain performance in muscle contraction. These regener-
ating cells are differently regulated than mature muscle cells and
there is certainly a regulatory molecular mechanism that could
favors Up71 expression in an early stage of myogenesis.
Preliminary results showed that expression level of Up71 in
primary myoblasts of mdx diaphragm was higher than that
observed when cells fused in myotubes (Hnia, K. and Mornet,
D., unpublished data).
The presence of Up71 protein appears particular and its
function needs to be identified by further studies. We need also
to define more precisely the regulatory molecular mechanism of
its expression, that could corresponds to novel alternate
mechanism, to hope mdx diaphragm and powerful all DMD
muscles with complete utrophin compensation as this is reached
in other mdx skeletal muscles where Up71 is absent.
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